首页> 外文期刊>Life sciences >Endothelin and endothelin receptors in the renal and cardiovascular systems
【24h】

Endothelin and endothelin receptors in the renal and cardiovascular systems

机译:肾和心血管系统中的内皮素和内皮素受体

获取原文
获取原文并翻译 | 示例
           

摘要

Endothelin-1 (ET-1) is a multifunctional hormone which regulates the physiology of the cardiovascular and renal systems. ET-1 modulates cardiac contractility, systemic and renal vascular resistance, salt and water renal reabsorption, and glomerular function. ET-1 is responsible for a variety of cellular events: contraction, proliferation, apoptosis, etc. These effects take place after the activation of the two endothelin receptors ET A and ET B, which are present - among others - on cardiomyocytes, fibroblasts, smooth muscle and endothelial cells, glomerular and tubular cells of the kidney. The complex and numerous intracellular pathways, which can be contradictory in term of functional response depending on the receptor type, cell type and physiological situation, are described in this review. Many diseases share an enhanced ET-1 expression as part of the pathophysiology. However, the use of endothelin blockers is currently restricted to pulmonary arterial hypertension, and more recently to digital ulcer. The complexity of the endothelin system does not facilitate the translation of the molecular knowledge to clinical applications. Endothelin antagonists can prevent disease development but secondary undesirable effects limit their usage. Nevertheless, the increasing understanding of the effects of ET-1 on the cardiac and renal physiology maintains the endothelin system as a promising therapeutic target.
机译:内皮素-1(ET-1)是一种多功能激素,可调节心血管和肾脏系统的生理功能。 ET-1调节心脏的收缩力,全身和肾脏的血管阻力,盐和水的肾脏重吸收以及肾小球功能。 ET-1负责多种细胞事件:收缩,增殖,凋亡等。这些作用发生在两种内皮素受体ET A和ET B激活后,它们存在于心肌细胞,成纤维细胞,肾的平滑肌和内皮细胞,肾小球和肾小管细胞。这篇综述描述了复杂而众多的细胞内途径,这些途径在功能反应方面可能是相互矛盾的,具体取决于受体类型,细胞类型和生理状况。作为病理生理学的一部分,许多疾病都具有增强的ET-1表达。但是,内皮素阻滞剂的使用目前仅限于肺动脉高压,最近仅限于数字溃疡。内皮素系统的复杂性不利于将分子知识转化为临床应用。内皮素拮抗剂可以预防疾病发展,但次要不良作用限制了它们的使用。然而,对ET-1对心脏和肾脏生理的影响的日益了解使内皮素系统成为有希望的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号